NCT02955940 - An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Pancreatic CancerColorectal Cancer (CRC)Breast CancerLung Cancer

Interventions

DRUG

Ruxolitinib

5 mg BID

DRUG

Capecitabine

Capecitabine at the same dose provided in the parent study at the time of the rollover.

DRUG

Regorafenib

Regorafenib at the same dose provided in the parent study at the time of the rollover.

Trial Locations (9)

New York Oncology Hematology Pc., Clifton Park

Tennessee Oncology, Nashville

University of Louisville, Louisville

University of Texas M. D. Anderson Cancer Center, Houston

Renovatio Clinical Consultants Llc, The Woodlands

UCLA Healthcare Hematology-Oncology, Santa Monica

Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii, Krakow

Samodzielny Publiczny Szpital Kliniczny, Lublin

Instytut Hematologii I Transfuzjologii, Warsaw